Trastuzumab deruxtecan
- Generic Name
- Trastuzumab deruxtecan
- Brand Names
- Enhertu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1826843-81-5
- Unique Ingredient Identifier
- 5384HK7574
- Background
Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...
- Indication
In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...
- Associated Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
- Associated Therapies
- -
Ongoing Research Seeks to Optimize Targeted Therapy Use in mCRC
Targeted therapies for metastatic colorectal cancer (mCRC) are moving to earlier treatment lines, emphasizing the importance of molecular testing. Key options include anti-EGFR therapy for RAS wild-type patients, BRAF V600E inhibitors like encorafenib, and HER2-directed therapies such as trastuzumab plus tucatinib. Ongoing trials aim to integrate these therapies into first-line settings, including MOUNTAINEER-03 for HER2-positive patients and studies on new RAS-targeted therapies.
Related Clinical Trials:
Maintained QOL, Neurological Function Support T-DXd Safety and Efficacy in HER2+ mBC
T-DXd showed favorable HRQOL and neurological function results in HER2+ metastatic breast cancer patients, with 12-month deterioration-free rates above 50% for cognitive, emotional, physical, and social functioning, and pain scores, regardless of stable or active brain metastases. Median treatment duration was 11.5 months, with 86.6% neurological stability at first score post baseline.
Related Clinical Trials:
Cancer Care Advancements in 2024 and Beyond
In 2024, ctDNA testing expanded in oncology, offering early cancer detection and treatment guidance. It provides peace of mind for some patients but may increase fear for others. Challenges remain in detecting ctDNA in certain cancers. Research continues to evolve ctDNA's role and cancer therapies, with ongoing advancements in cancer care.
Pancreatic Cancer: A Look Back at 2024
2024 saw progress in pancreatic cancer treatment with four new drug approvals, a phase 3 trial showing survival benefits, and the first phase 3 RAS inhibitor trial. The five-year survival rate rose to 13%, though pancreatic cancer remains challenging. Targeted therapies and biomarker testing are crucial, with new options like NALIRIFOX, KRAS inhibitors, and TTFields offering hope.
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
Project EVOLVE finds lower ILD incidence in HER2+ breast cancer patients (4.17%) vs. literature (10-14%). AI-powered health record analytics and targeted education improve ILD management, enhancing patient and provider outcomes. HER2-targeted therapies improve survival but require careful ILD monitoring. Real-world data offers unique insights differing from clinical trials, potentially reshaping AE monitoring protocols.
T-DXd Preserves QOL, Neurological Function in HER2+ Metastatic Breast Cancer
DESTINY-Breast12 trial findings show T-DXd maintains HRQOL and neurological function in HER2-positive metastatic breast cancer patients with or without brain metastases. Estimated 12-month deterioration-free rates for cognitive, emotional, physical, and social functioning, as well as pain, were above 50%. Median treatment duration was 11.5 months, with 118 patients still receiving T-DXd at data cutoff.
Related Clinical Trials:
Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management
Targeted therapies, including KRAS, BRAF, and CLDN18.2 inhibitors, are transforming treatment for pancreatic, colorectal, lung, and gastric cancers. Experts highlight improved response rates and survival with molecular profiling-guided treatments, emphasizing the importance of biomarker expression for treatment selection and sequencing.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath